Peer-reviewed veterinary case report
Vaccine with BCG lowers visceral leishmaniasis in dogs in Iran trial
By Mohebali, Mehdi et al.·Published in Vaccine·2004·School of Public Health and Institute of Public Health Research·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran.
- Species:
- dog
Plain-English summary
A group of 347 healthy dogs were given either a new vaccine for Leishmania (a parasite that can cause serious illness) mixed with BCG or a placebo to see how well it protected them from canine visceral leishmaniasis. After 16 months, the vaccinated dogs had a much lower rate of infection (3.7%) compared to those that received the placebo (12%). The vaccine was found to be safe and well-tolerated, showing an overall effectiveness of about 69%. This means that the vaccine could be a good option for protecting dogs from this disease.
People also search for: dog leishmaniasis vaccine · canine visceral leishmaniasis treatment · Leishmania vaccine efficacy in dogs
Abstract
This study was designed to evaluate the efficacy of a single dose of aluminum hydroxide (alum) precipitated Leishmania major (Alum-ALM) vaccine plus BCG against canine visceral leishmaniasis. Three hundred and forty-seven healthy dogs with no anti-Leishmania antibodies were double-blind randomly injected intradermally with either 0.1ml of Alum-ALM (200 microg protein) mixed with BCG (182 dogs) or injected with 0.1ml of normal saline (165 dogs). The results of 16 months follow-up showed that the vaccine was safe and well-tolerated. Strong seroconversion using DAT and ELISA techniques at 16 months post-vaccination was considered as an indication of Leishmania infection. The incidence rate was 3.7% (6/162) in vaccinated group and 12.0% (17/141) in control group using DAT technique. The efficacy of the vaccine was calculated to be 69.3%.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15364462/